lutetium and taxane
lutetium has been researched along with taxane in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Barber, TW; Baum, RP; Billah, B; Kulkarni, HR; Niepsch, K; Singh, A | 1 |
| Antonarakis, ES; Denmeade, SR; Eisenberger, MA; Eshleman, JR; Isaacsson Velho, P; Luo, J; Paller, CJ; Piana, D; Pomper, MG; Riel, S; Rowe, SP | 1 |
| Jacene, H; Ravi, P; Shah, H; Sonpavde, G | 1 |
| Bal, C; Sahoo, RK; Satapathy, S | 1 |
Reviews
2 review(s) available for lutetium and taxane
| Article | Year |
|---|---|
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
Topics: Clinical Trials, Phase II as Topic; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2022 |
[
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
Other Studies
2 other study(ies) available for lutetium and taxane
| Article | Year |
|---|---|
Clinical Outcomes of
Topics: Aged; Aged, 80 and over; Bridged-Ring Compounds; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Safety; Taxoids; Time Factors; Treatment Outcome | 2019 |
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Bridged-Ring Compounds; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; RNA, Messenger; Taxoids; Treatment Outcome | 2019 |